Syngene International gets ₹8.62 Cr refund for AY 2014-15

1 min read     Updated on 08 Jul 2026, 05:11 AM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Syngene International secured a ₹8.62 Cr refund for Assessment Year 2014-15 following an NFAC order. The refund reduces contingent liability, though the amount is yet to be credited.

powered bylight_fuzz_icon
44978694

*this image is generated using AI for illustrative purposes only.

Syngene International has secured a refund of ₹8.62 Cr for Assessment Year 2014-15 after tax authorities gave effect to an order passed by the National Faceless Appeal Centre (NFAC). The order, dated May 14, 2026, was received by the company on July 6, 2026, and concludes a litigation process that began with an initial demand of ₹16.72 Cr in 2016. While the refund amount is yet to be credited, the development will lead to a decrease in the company's contingent liability related to the financial period in question.

The dispute originated when the Deputy Commissioner of Income-tax, Circle 6(1)(1), Bangalore, passed an order under Section 143(3) of the Income Tax Act on December 23, 2016. This order disallowed certain deductions claimed by Syngene International and raised a demand of ₹16,72,20,900. Following an appeal filed by the company on January 24, 2017, the Assessing Officer passed a subsequent order under Section 154 of the Act on March 8, 2017, increasing the total demand to ₹33,69,27,800.

The NFAC intervened with an order under Section 250 of the Act dated February 13, 2026, partly allowing the company's appeal. The recent order from the Assessing Officer implements this NFAC decision, formally granting a refund of ₹8,62,14,600, which includes interest. Syngene International stated that it is currently analysing the order to determine if any further action is required.

Financial Implications

Syngene International stated that the order does not expect to have a material impact on its financials, operations, or activities. The primary accounting effect will be a reduction in the contingent liability associated with the Assessment Year 2014-15. No penalties, restrictions, or sanctions were imposed in the order.

Litigation Timeline

Date Event
December 23, 2016 Initial order passed under Section 143(3) raising demand of ₹16,72,20,900
January 24, 2017 Company filed appeal against the disallowance
March 8, 2017 Assessing Officer passed order under Section 154 increasing demand to ₹33,69,27,800
February 13, 2026 NFAC passed order under Section 250 partly allowing the appeal
May 14, 2026 Order passed giving effect to NFAC order granting refund of ₹8,62,14,600
July 6, 2026 Communication received via SMS and downloaded from income tax website

Historical Stock Returns for Syngene International

1 Day5 Days1 Month6 Months1 Year5 Years
-0.21%-2.51%-8.53%-33.43%-33.01%-28.16%

Will the successful resolution of this decade-long tax dispute encourage Syngene to pursue similar appeals for other pending litigations?

How will the reduction in contingent liabilities impact Syngene's credit ratings and borrowing costs in the near future?

Does the NFAC's decision set a favorable precedent for other pharmaceutical companies facing similar tax disallowances?

like17
dislike

Syngene AGM to vote on dividend and appoint Siddharth Mittal as MD & CEO

3 min read     Updated on 04 Jul 2026, 06:08 AM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Syngene International will hold its 33rd AGM on July 29, 2026, via Video Conferencing to vote on a final dividend of ₹1.25 per share for FY26 and appoint Mr. Siddharth Mittal as MD & CEO for five years. The company reported consolidated revenue of ₹37,387 Mn for FY26, with a PAT of ₹3,167 Mn after exceptional items. Remote e-voting is open from July 24 to July 28, 2026.

powered bylight_fuzz_icon
43851777

*this image is generated using AI for illustrative purposes only.

Syngene International has scheduled its 33rd Annual General Meeting (AGM) for Wednesday, July 29, 2026, at 3:30 PM IST via Video Conferencing. Shareholders will vote on a final dividend of ₹1.25 per equity share for the financial year ended March 31, 2026. The record date to determine eligibility is Friday, June 26, 2026. The meeting will also consider the appointment of Mr. Siddharth Mittal as Managing Director and Chief Executive Officer for a five-year term effective July 01, 2026, with a proposed annual remuneration of ₹25 crore.

Key AGM Resolutions

The following table summarises the key resolutions to be considered at the 33rd AGM:

Resolution: Details
Dividend: ₹1.25 per share for FY26
MD & CEO Appointment: Mr. Siddharth Mittal for 5 years from July 01, 2026
Auditor Appointment: M/s S. R. Batliboi & Associates LLP for 5 years
Director Remuneration: Up to 15% of net profits for FY 2026–27 to FY 2028–29
Independent Director: Dr. Vijaya Chandru for 3 years from July 29, 2026
Independent Director: Dr. Arun Chandavarkar for 3 years from July 29, 2026
Non-Executive Director: Ms. Vinita Bali from July 22, 2026 to July 21, 2027
Director Re-appointment: Prof. Catherine Rosenberg, liable to retire by rotation

Leadership Transition and MD & CEO Remuneration

The Board recommends the appointment of Mr. Siddharth Mittal as Managing Director and Chief Executive Officer for a five-year term effective July 01, 2026. His proposed annual remuneration totals ₹25 crore, comprising fixed compensation of ₹10 crore, short-term incentives of ₹5 crore, and long-term incentives of ₹10 crore. Mr. Siddharth Mittal previously served as Managing Director and CEO of Biocon Limited, bringing over two decades of experience in strategic finance, M&A, and general management.

FY26 Financial Performance

Syngene reported consolidated revenue from operations of ₹37,387 Mn for FY26, up 3% year-on-year, with an Operating EBITDA margin of 25%. Profit after tax before exceptional items stood at ₹3,799 Mn. The company recognised exceptional items amounting to a net loss of ₹632 Mn, primarily relating to gratuity re-measurement following the notification of new Labour Codes and termination benefits extended to employees. After accounting for exceptional items, profit after tax for FY26 stood at ₹3,167 Mn. The company generated ₹5,207 Mn in net cash during the year and closed with a net cash position of approximately ₹18,003 Mn after funding capital expenditure.

The following table presents key standalone and consolidated financial metrics:

Metric: Standalone FY26 Standalone FY25 Consolidated FY26 Consolidated FY25
Revenue from Operations: ₹34,907 Mn ₹34,438 Mn ₹37,387 Mn ₹36,424 Mn
EBITDA (excl. exceptional): ₹8,815 Mn ₹9,882 Mn ₹9,892 Mn ₹11,136 Mn
Profit After Tax (excl. exceptional): ₹3,049 Mn ₹4,680 Mn ₹3,799 Mn ₹4,962 Mn
Profit After Tax (incl. exceptional): ₹3,167 Mn ₹4,962 Mn

Subsidiary Performance

Syngene has three wholly owned subsidiaries. Syngene USA Inc. reported revenue of USD 12.25 million with a loss of USD 1.4 million. Syngene Scientific Solutions Limited generated total income of INR 4,255 million with a profit before tax of INR 287 million. Syngene Manufacturing Solutions Limited reported a total income of INR 0.6 million with a loss of INR 0.035 million and is yet to commence operations.

E-Voting and AGM Logistics

The company has appointed KFin Technologies Limited as the Registrar and Transfer Agent to facilitate e-voting and AGM proceedings. Remote e-voting will be open from Friday, July 24, 2026 (09:00 hours IST) to Tuesday, July 28, 2026 (17:00 hours IST). Shareholders must ensure their bank details and PAN are updated to receive dividend payments electronically and comply with Tax Deduction at Source (TDS) regulations. The AGM Notice and Annual Report for FY 2025-26 are available on the company's website at https://www.syngeneintl.com/investors/share-holder-services/ .

Historical Stock Returns for Syngene International

1 Day5 Days1 Month6 Months1 Year5 Years
-0.21%-2.51%-8.53%-33.43%-33.01%-28.16%

How will Mr. Siddharth Mittal's strategic leadership influence Syngene's growth trajectory and M&A activity over the next five years?

What measures will the new management implement to reverse the decline in EBITDA margins observed in FY26?

How does the company plan to utilize the substantial net cash balance of ₹18,003 Mn to drive future value for shareholders?

like18
dislike

More News on Syngene International

Must Read Next

Earnings

Corporate Actions

Stocks

1 Year Returns:-33.01%